预约演示
更新于：2024-12-31
Deutetrabenazine
氘丁苯那嗪
更新于：2024-12-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2017-04-03), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、孤儿药 (美国)、优先审评 (中国)、孤儿药 (韩国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C19H27NO3 |
InChIKeyMKJIEFSOBYUXJB-QBUQIWBYSA-N |
CAS号1392826-25-3 |
关联
19
项与 氘丁苯那嗪 相关的临床试验CTR20233248
一项评价单次给药12 mg安泰坦®片剂在健康中国受试者中的氘丁苯那嗪及其活性代谢物的药代动力学特征的开放性、单剂量研究
ChiCTR2300076925
An Open-label, Single Dose Trial to Characterize the Pharmacokinetics of Deutetrabenazine and its Active Metabolites in Healthy Chinese Participants After a Single Dose of a 12-mg AUSTEDO® Tablet
CTR20233106
随机、开放、两制剂、两序列、四周期、完全重复交叉设计评估中国健康受试者空腹/餐后状态下口服氘丁苯那嗪片的人体生物等效性试验
100 项与 氘丁苯那嗪 相关的临床结果
登录后查看更多信息
100 项与 氘丁苯那嗪 相关的转化医学
登录后查看更多信息
100 项与 氘丁苯那嗪 相关的专利（医药）
登录后查看更多信息
64
项与 氘丁苯那嗪 相关的文献（医药）2023-11-01Current medicinal chemistry
Clinical Application and Synthesis Methods of Deuterated Drugs
Article
作者: Rao, Guo-Wu ; Zhang, Wen ; Xu, Xiao-Liang
Abstract::
Many drugs have adverse absorption, distribution, metabolism, and excretory
(ADME) properties that prevent their widespread use or limit their use in some indications.
In addition to preparation techniques and prodrug strategies, deuterium modification
is a viable method for improving ADME properties. Deuterated drugs have attracted
increasing attention from the pharmaceutical industry in recent years. To date, two deuterated
drugs have been approved by the FDA. In 2017, austedo was approved by the FDA
as a new drug for Huntington's disease in the United States, the first deuterium drug to be
marketed worldwide. Recently (June 9, 2021), donafinil has been listed in China; this result
has caused major pharmaceutical companies and the pharmaceutical industry to pay
attention to deuterium technology again. In addition, BMS-986165, RT001, ALK-001,
HC-1119, AVP-786 and other drugs are in phase III clinical studies, and some solid deuterium
compounds have entered phase I and II clinical trials. The deuterium strategy has
been widely used in pharmaceutical research and has become a hot spot in pharmaceutical
research in recent years. In this paper, the research and development of deuterated
drugs are reviewed, and the influence of deuterium modification on drugs, the advantages
of deuterium strategies and the synthesis strategies of deuterated drugs are mainly
introduced. Hoping to provide references for clinical application, the discovery of new
deuterium chemical entities and research and development of new deuterated drugs.
2023-04-01Current neuropharmacology
The Emerging Landscape of Natural Small-molecule Therapeutics for
Huntington’s Disease
Review
作者: Nazir, Aamir ; Siddique, Yasir Hassan ; Dar, Nawab John ; Bhat, Shahnawaz Ali ; Ahamad, Shakir
Abstract::
Huntington’s disease (HD) is a rare and fatal neurodegenerative disorder with no disease modifying therapeutics. HD is characterized by extensive neuronal loss and is caused by the inherited expansion of the huntingtin (HTT) gene that encodes a toxic mutant HTT (mHTT) protein having expanded polyglutamine (polyQ) residues. Current HD therapeutics only offer symptomatic relief. Infact, Food and Drug Administration (FDA) approved two synthetic small-molecule VMAT2 inhibi-tors, tetrabenazine (1) and deutetrabenazine (2), for managing HD chorea and various other diseases in clinical trials. Therefore, the landscape of drug discovery programs for HD is evolving to discover disease-modifying HD therapeutics. Likewise, numerous natural products are being evaluated at different stages of clinical development and have shown the potential to ameliorate HD pathology. The inherent anti-inflammatory and antioxidant properties of natural products mitigate the mHTT-induced oxidative stress and neuroinflammation, improve mitochondrial functions, and augment the anti-apoptotic and pro-autophagic mechanisms for increased survival of neurons in HD. In this review, we have discussed HD pathogenesis and summarized the anti-HD clinical and pre-clinical natural products, focusing on their therapeutic effects and neuroprotective mechanisms.
2022-08-26Cureus
Group A Beta-Hemolytic Streptococcus-Induced Tic-Like Movement Disorder in an Adult: A Case Report
作者: Ilyas, Usman ; Lin, Dana ; Umar, Zaryab
A tic is a sudden, repeated, quick, and uncontrollable movement of a part of the body. Tic disorders have a multifactorial etiology, including genetic predisposition, autoimmunity, and environmental factors. Movement disorders following streptococcal infection are rare and typically present in the pediatric population. We present a unique case of a 31-year-old female admitted with involuntary movements of the upper extremities of three weeks duration. Her movements start as twitching before progressing to one hand hitting the other or hitting her face. She had a strong urge before giving in to complete the action. However, the movements were partially distractable, with considerable overlap between clinical features of organic and functional tics. After a detailed workup, including a negative magnetic resonance imaging (MRI) of the brain with and without contrast, MRI of the spine, computed tomography of the chest, abdomen, and pelvis for neoplasia, as well as blood work for autoimmunity, infections, and paraneoplastic syndrome, the serology came back strongly positive for antistreptolysin O and antideoxyribonuclease B titers. Additionally, a detailed psychiatric assessment ruled out conversion disorder leading to a diagnosis of streptococcus-induced movement disorder. After a failed inpatient trial of aripiprazole, the plan included initiating deutetrabenazine with close outpatient neurology follow-up after discharge.
100 项与 氘丁苯那嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 舞蹈症 | 中国 | 2020-06-08 | |
| 迟发性运动障碍 | 美国 | 2017-08-30 | |
| 亨廷顿舞蹈病 | 美国 | 2017-04-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脑瘫 | 临床3期 | 美国 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 比利时 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 加拿大 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 丹麦 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 以色列 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 意大利 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 波兰 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 俄罗斯 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 斯洛伐克 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 西班牙 | 2019-08-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 願顧簾窪鑰選糧積膚襯(蓋繭網築膚醖獵範繭餘) = 鑰觸憲鬱獵簾鹹鑰鹽鹹 構窪鑰淵獵製製積簾簾 (獵構選衊襯獵鏇範蓋願 ) 更多 | 积极 | 2024-09-23 | |||
Placebo | - | ||||||
临床3期 | 80 | 淵膚簾鏇廠鹽範夢憲構(鏇廠觸鹽衊繭窪醖製繭) = 糧窪壓鹹鏇鬱構鏇襯膚 衊鬱鑰艱製繭膚簾遞膚 (憲齋製簾壓壓願膚顧齋 ) 更多 | 积极 | 2024-06-28 | |||
临床3期 | 44 | 鹽醖窪願襯構餘鬱餘齋(範糧獵夢壓鹹繭蓋糧鏇) = 餘遞廠糧繭鬱齋鹹鬱艱 鬱壓襯憲顧構網鹹顧窪 (糧構壓積膚膚膚選夢鑰, 構膚製鑰鏇顧鑰鬱遞壓 ~ 壓鹹窪構顧蓋遞蓋鬱襯) 更多 | - | 2024-04-22 | |||
N/A | - | 齋選範鑰鏇觸鬱簾範鹹(壓餘齋製觸網壓壓願築) = 願觸簾積鏇願糧鬱壓觸 憲淵餘窪蓋齋夢窪蓋願 (觸襯膚製壓襯繭夢觸鏇, 6) 更多 | - | 2024-04-09 | |||
临床4期 | - | 築顧構壓構艱製網鹹淵(膚餘淵構積構遞網鬱簾) = 廠襯選遞壓鏇艱顧餘淵 鹽網壓淵鹽構醖鏇艱顧 (夢觸餘築鏇鑰鑰夢衊構 ) 更多 | 积极 | 2023-11-02 | |||
临床3期 | 63 | Placebo (Placebo) | 襯艱製觸鏇襯繭鏇選願(願獵鏇醖積蓋獵壓鏇遞) = 廠糧鹽網鹽齋窪憲選鹹 築觸願繭鹽顧顧夢衊衊 (衊膚鑰膚選夢繭網選鏇, 糧膚選鏇積願廠鬱艱夢 ~ 製網膚觸構夢遞觸網網) 更多 | - | 2023-09-08 | ||
(TEV-50717) | 襯艱製觸鏇襯繭鏇選願(願獵鏇醖積蓋獵壓鏇遞) = 選鏇鏇餘廠觸築襯餘齋 築觸願繭鹽顧顧夢衊衊 (衊膚鑰膚選夢繭網選鏇, 築淵繭鹽獵構壓鏇憲選 ~ 廠鏇糧構餘構鬱獵願壓) 更多 | ||||||
N/A | - | 齋壓鹹廠憲鹹襯鬱鬱鬱(襯鑰顧網顧窪積壓憲構): relative treatment effects = -1.87 (95% CI, -3.23 ~ -0.52) | - | 2023-08-27 | |||
FDA 人工标引  | N/A | 113 | 憲夢憲鑰齋夢齋製網鑰(襯鏇鹹鏇衊蓋獵膚齋醖) = 遞鹹選膚衊襯憲鹽簾餘 膚鬱鏇簾壓願積鏇淵鹽 (鑰構艱鏇衊鹹築齋簾遞, 0.45) | 积极 | 2023-02-17 | ||
Placebo | 憲夢憲鑰齋夢齋製網鑰(襯鏇鹹鏇衊蓋獵膚齋醖) = 繭齋膚鏇艱壓醖簾顧夢 膚鬱鏇簾壓願積鏇淵鹽 (鑰構艱鏇衊鹹築齋簾遞, 0.46) | ||||||
FDA 人工标引 | N/A | 222 | 構願鹹繭願構製顧鬱襯(顧淵齋簾糧鏇膚糧憲糧) = 繭鹹鏇構壓膚糧餘壓積 廠壓鏇鑰廠選簾選製鑰 (壓選憲鑰窪積構願選壓, 0.42) | 积极 | 2023-02-17 | ||
構願鹹繭願構製顧鬱襯(顧淵齋簾糧鏇膚糧憲糧) = 鑰積壓齋鏇獵製簾繭醖 廠壓鏇鑰廠選簾選製鑰 (壓選憲鑰窪積構願選壓, 0.45) | |||||||
临床3期 | 119 | (Rollover) | 選鹽鏇夢窪獵鑰積夢襯(構窪繭餘膚網簾蓋夢蓋) = Adverse events of interest included suicidality (9%; 5%) and parkinsonism (4%; 8%). 膚網鬱遞築選簾鏇網廠 (鏇衊繭築遞壓衊鑰顧構 ) 更多 | 积极 | 2022-10-15 | ||
Deutetrabenazine+tetrabenazine (Switch) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用